Evaluation of neurotoxic potential by use of in vitro systems

Expert Opinion on Drug Metabolism and Toxicology

Volumn 1, Issue 4, 2005, Pages 701-713

  Harry, Gaylia Jean ^a   Tiffany Castiglioni, Evelyn ^b  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

Author keywords

cisplatin; cytotoxicity; glia; neurons; neurotoxicity screening

Indexed keywords

ANIMAL; ANIMAL TESTING ALTERNATIVE; BLOOD BRAIN BARRIER; CELL LINE; CELL SURVIVAL; DRUG EFFECT; HUMAN; IN VITRO STUDY; LEARNING; METHODOLOGY; NERVOUS SYSTEM; NEURITE; ORGAN CULTURE TECHNIQUE; PHYSIOLOGY; REVIEW; TOXICITY TESTING;

ANIMAL TESTING ALTERNATIVES; ANIMALS; BLOOD-BRAIN BARRIER; CELL LINE; CELL SURVIVAL; HUMANS; LEARNING; NERVOUS SYSTEM; NEURITES; ORGAN CULTURE TECHNIQUES; TOXICITY TESTS;

EID: 33747140473     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.1.4.701     Document Type: Review

References (88)

1. GOLDBERG AM: An approach to the development of in vitro toxicological methods. Food Chem. Toxicol. (1985) 23:205-208. (Pubitemid 15004648)
2. SCALA RA: Theoretical approaches to validation. In:In vitro Toxicology Approaches to Validation. Alternative Methods in Toxicology, Vol 5. AM Goldberg (Ed.), Mary Ann Liebert, New York, US (1987):1-10.
3. WILLIAMS SP, DAVENPORT-JONES J, EGAN C et al.: Phase I of an in vitro neurotoxicological prevalidation trial. Toxicol. In Vitro (1994) 8:799-802. (Pubitemid 24312782)
4. LIEB K, TREFFURTH, HAMKE M et al.: Evaluation of the use of in vitro methodologies as tools for screening new compounds for potential in vivo toxicity. Toxicol. In Vitro (2001) 15:571-577.
5. ASCHNER M, SYVERSEN T: Neurotoxicology: principles and considerations of in vitro assessment. Altern. Lab. Anim. (2004) 32(4):323-327. (Pubitemid 40139207)
6. TIFFANY-CASTIGLIONI E, EHRICH M, DEES L et al.: Bridging the gap between in vitro and in vivo models for neurotoxicology. Toxicol. Sci. (1999) 51(2):178-183. (Pubitemid 29496224)
7. TIFFANY-CASTIGLIONI E: In vitro Neurotoxicology: Principles and Challenges. Humana Press, Inc., Totowa, NJ, USA (2004).
8. HARRY GJ, BILLINGSLEY M, BRUININK A et al.: In vitro techniques for the assessment of neurotoxicity. Environ. Health Perspect. (1998) 106:131-158. (Pubitemid 28196041)
9. ARAQUE A, PEREA G: Glial modulation of synaptic transmission in culture. Glia (2004) 47(3):241-248. (Pubitemid 39121069)
10. HARRY GJ: Basic principles of disturbed CNS and PNS functions. In:Introduction to neurobehavioral toxicology: Food and environment. RJM Niesink, RMA Jaspers, LMV Kornet, JM van Ree, HA Tilson (Eds), CRC Press, Boca Raton, FL, USA (1999):115-162.
11. PARDRIDGE W: Introduction to blood- brain barrier. Cambridge University Press, Cambridge, UK (1998).
12. PARDRIDGE WM: Drug and gene targeting to the brain with molecular Trojan horses. Nat. Rev. Drug Discov. (2002) 1(2):131-139. (Pubitemid 41646520)
13. TERASAKI T, OHTSUKI S, HORI S, TAKANAGA H, NAKASHIMA E, HOSOYA K: New approaches to in vitro models of blood-brain barrier drug transport. Drug Discov. Today (2003) 8(20):944-954. (Pubitemid 37230014)
14. TAHTI H, NEVALA H, TOIMELA T: Refining in vitro neurotoxicity testing - the development of blood-brain barrier models. Altern. Lab. Anim. (2003) 31:273-276. (Pubitemid 36950599)
15. HASELOFF RF, BLASIG IE, BAUER HC, BAUER H: In search of the astrocytic factor(s) modulating blood-brain barrier functions in brain capillary endothelial cells in vitro. Cell Mol. Neurobiol. (2005) 25(1):25-39. (Pubitemid 40558583)
16. SCHIERA G, SALA S, GALLO A et al.: Permeability properties of a three-cell type in vitro model of blood-brain barrier. J. Cell Mol. Med. (2005) 9(2):373-379.
17. WALUM E, NORDIN M, BECKMAN M, ODLAN L: Cellular methods for identification of neurotoxic chemicals and estimation of neurotoxicological risk. Toxicol. In Vitro (1993) 7:321-326.
18. BRUININK A, YU D, MAIER P: Shortterm assay for the identification of neurotoxic compounds and their liver derived stable metabolites. Toxicol. In Vitro (2002) 16:717-724. (Pubitemid 35356279)
19. HEIKKILA RE, HESS A, DUVOISIN RC: Dopaminergic neurotoxicity of 1-methyl-4- phenyl-1,2,5,6-tetrahydropyridine in mice. Science (1984) 224:1451-1453. (Pubitemid 14123348)
20. LANGSTON JW, FORNO LS, REBERT CS, IRWIN I: Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,3,5,6- tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res. (1984) 292:390-394. (Pubitemid 14190114)
21. DESAGHER S, GLOWINSKI J, PREMONT J: Astrocytes protect neurons from hydrogen peroxide toxicity. J. Neurosci. (1996) 16:2553-2562. (Pubitemid 26122677)
22. DRINGEN R, PFEIFFER B, HAMPRECHT B: Synthesis of the antioxidant glutathione in neurons: supply by astrocytes of CysGly as a precursor for neuronal glutathione. J. Neurosci. (1999) 19:562-569. (Pubitemid 29036007)
23. GREENE LA, TISCHLER AS: Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc. Natl. Acad. Sci. USA (1976) 73:2424-2428.
24. GUROFF G: PC12 cells as model of neuronal differentiation. In:Cell Culture in the Neurosciences. JE Bottenstein, G Sato, (Eds), Plenum Publishing, New York, US (1985):245-272.
25. FUJITA K, LAZAROXICI P, GUROFF G: Regulation of the differentiation of PC-12 pheochromocytoma cells. Environ. Health Perspect. (1989) 80:127-142. (Pubitemid 19084670)
26. SHASTRY P, BASU A, RAJADHYAKSHA MS: Neuroblastoma cell lines - a versatile in vitro model in neurobiology. Int. J. Neurosci. (2001) 108(1-2):109-126. (Pubitemid 32832140)
27. SPENGLER BA, ROSS RA, BIEDLER JL: Differential drug sensitivity of human neuroblastoma cells. Cancer Treat. Rep. (1986) 70(8):959-965. (Pubitemid 16041855)
28. HAMPRECH B: Structural, electrophysiological, biochemical and pharmacological properties of neuroblastoma-glioma cell hybrids in culture. Int. Rev. Cytol. (1977) 49:99-170.
29. DURHAM HD, DAHROUGH S, CASHMAN S: Evaluation of the spinal cord neuron X neuroblastoma hybrid cell line NSC-34 as a model for neurotoxicity testing. Neurotoxicology (1993) 14:387-396. (Pubitemid 24032690)
30. BIGNAMI A, DAHL D, RUEGER DC: Glial fibrillary acidic proteins in normal cells and in pathological conditions. Adv. Cell Neurobiol. (1980) 1:285-309.
31. COOKSON MR, PENTREATH VW: Alterations in the glial fibrillary acid protein content of primary astrocyte cultures for evaluation of glial cell toxicity. Toxicol. In Vitro (1994) 8:351-359. (Pubitemid 24219168)
32. STOPPINI L, BUCHS LA, MULLER D: A simple method for organotypic cultures of nervous tissue. J. Neurosci. Methods (1991) 37:173.
33. NORABERG J: Organotypic brain slice cultures: an efficient and reliable method for neurotoxicological screening and mechanistic studies. Altern. Lab. Anim. (2004) 32(4):329-337. (Pubitemid 40139208)
34. ABDEL-HAMID KM, TYMIANSKI M: Mechanisms and effects of intracellular calcium buffering on neuronal survival in organotypic hippocampal cultures exposed to anoxia/aglycemia or to excitotoxins. J. Neurosci. (1997) 17:3538-3553. (Pubitemid 27200582)
35. ADAMCHIK Y, FRANTSEVA MV, WEISSPAPIR M, CARLEN PL, PEREZ-VELAZQUEZ JL: Methods to induce primary and secondary traumatic damage in organotypic hippocampal slice cultures. Brain Res. Protocols (2000) 5:153-158. (Pubitemid 30210033)
36. KRISTENSEN BW, NORABERG J, ZIMMER J: Comparison of excitotoxic profiles of ATPA, AMPA, KA and MNDA in organotypic hippocampal slice cultures. Brain Res. (2001) 917:21-44. (Pubitemid 32973195)
37. KRISTENSEN BW, NORABERG J, THIEBAUD P, KOUDELKA-HEP M, ZIMMER J: Biocompatibility of siliconbased arrays of electrodes coupled to organotypic hippocampal brain slice cultures. Brain Res. (2001) 896:1-17. (Pubitemid 32244141)
38. PENTREATH VW: Neurotoxicology in vitro. Taylor and Francis, London, UK (1999).
39. SMITH SL, SADLER CJ, DODD CC et al.: The role of glutathione in the neurotoxicity of artemisinin derivatives in vitro. Biochemical Pharmacol. (2001) 61(4):409-416. (Pubitemid 32168222)
40. SCRENCI D, MCKEAGE MJ: Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches. Oncol. Res. (1999) 11(6):287-293.
41. DONZELLI E, CARFI M, MILOSO M, STRADA A, GALBIATI S, BAYSSAS M: Neurotoxicity of platinum compounds: comparison of the effects of cisplatin and oxaliplatin on the human neuroblastoma cell line SH-SY5Y. J. Neurooncol. (2004) 67(1-2):65-73. (Pubitemid 38418250)
42. RZESKI W, PRUSKIL S, MACKE A et al.: Anticancer agents are potent neurotoxins in vitro and in vivo. Ann. Neurol. (2004) 56:351-360. (Pubitemid 39166554)
43. SLAMON N, WARD TH, BUTLER J, PENTREATH VW: Assessment of DNA damage in C6 glioma cells after antidepressant treatment using an alkaline comet assay. Arch. Toxicol. (2001) 75:243-250. (Pubitemid 32524355)
44. NOH JS, HYO JK, KIM EY et al.: Haloperidol-induced neuronal apoptosis: role of p38 and c-Jun-NH2-terminal protein kinase. J. Neurochem. (2002) 75:2327-2334.
45. SPAHR-SCHOPFER I, VUTSKITS L, TONI N, BUCHS PA, PARISI L, MULLER D: Differential neurotoxic effects of propofol on dissociated cortical cells and organotypic hippocampal cultures. Anesthesiology (2000) 92(5):1408-1417. (Pubitemid 30257203)
46. PAVONE A, CARDILE V: An in vitro study of new antiepileptic drugs and astrocytes. Epilepsia (2003) 44(Suppl. 10):34-39. (Pubitemid 37280391)
47. GAO WQ, DYBDAL N, SHINSKY N et al.: Neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathy. Ann. Neurol. (1995) 38:30-37.
48. ARAUJO IM, AMBROSIO AF, LEAL EC et al.: Neurotoxicity induced by antiepileptic drugs in cultured hippocampal neurons: a comparative study between carbamazepine, oxcarbazepin, and two new putative antiepileptic drugs, BIA 2-024 and BIA 2-093. Epilepsia (2004) 45(12):1498-1505. (Pubitemid 39648274)
49. CHEUNG NS, KOH CH, BAY BH et al.: chronic exposure to U18666A induces apoptosis in cultured murine cortical neurons. Biochem. Biophys. Res. Commun. (2004) 315(2):408-417. (Pubitemid 38183122)
50. LANIGAN C, SURY M, BINGHAM R, HOWARD R, MACKERSIE A: Neurological sequelae in children after prolonged propofol infusion. Anaesthesia (1992) 47:810-811.
51. TROTTER C, SERPELL MG: Neurological sequelae in children after prolonged propofol infusion. Anaesthesia (1992) 47:340-342.
52. FINLEY GA, MACMANUS B, SAMPSON SE, FERNANDEZ CV, RETALLICK R: Delayed seizures following sedation with propofol. Can. J. Anaesth. (1993) 40:863-865. (Pubitemid 23325794)
53. MCFARLAN CS, ANDERSON BJ, SHORT TG: The use of propofol infusions in paediatric anaesthesia: a practical guide. Paediatr. Anaesth. (1999) 9(3):209-216. (Pubitemid 29220117)
54. HONEGGER P, MATTHIEU JM: Selective toxicity of the general anesthetic propofol for GABAergic neurons in rat brain cell cultures. J. Neurosci. Res. (1996) 45:631-636. (Pubitemid 26293363)
55. LUBRICH B, VAN CALKER D: Inhibition of the high affinity myo-inositol transport system: a common mechanism of action of antibipolar drugs? Neuropsychopharmacol. (1999) 21(4):519-529. (Pubitemid 29414797)
56. CHEN G, MANJI HK, WRIGHT CB, HAWVER DB, POTTER WZ: Effects of valproic acid on â-adrenergic receptors, G-proteins, and adenylyl cyclase in rat C6 glioma cells. Neuropsychopharmacol. (1996) 15:271-280. (Pubitemid 26285657)
57. CHEN G, HASANAT KA, BEBCHUK JM, MOORE GJ, GLITZ D, MANJI HK: Regulation of signal transduction pathways and gene expression by mood stabilizers and antidepressants. Psychosomatic Med. (1999) 61(5):599-617. (Pubitemid 29455084)
58. FIEBICH BL: Valproic acid inhibits substance P-induced activation of protein kinase C-å and expression of the substance P receptor. J. Neurochem. (2003) 86(1):69-76. (Pubitemid 36753847)
59. WANG JF, AZZAM JE, YOUNG LT: Valproate inhibits oxidative damage to lipid and protein in primary cultured rat cerebrocortical cells. Neurosci. (2003) 116(2):485-489. (Pubitemid 36139918)
60. BOWDEN CL, JANICAK PG, ORSULAK P et al.: Relation of serum valproate concentration to response in mania. Am. J. Psychiatry (1996) 153(6):765-770. (Pubitemid 26170536)
61. FADEN AI, MOVSESYAN VA, KNOBLACH SM, AHMED F, CERNAK I: Neuroprotective effects of novel small peptides in vitro and after brain injury. Neuropharmacol. (2005) 19.
62. ANDERSEN JK: Oxidative stress in neurodegeneration: cause or consequence. Nat. Med. (2004) 10:S18-S25. (Pubitemid 38901863)
63. VAIRANO M, GRAZIANI G, TENTORI L, TRINGALI G, NAVARRA P, DELLO RUSSO C: Primary cultures of microglial cells for testing toxicity of anticancer drugs. Toxicol. Lett. (2004) 148(1-2):91-94. (Pubitemid 38264524)
64. COLE GM, MORIHARA T, LIM GP, YANG F, BEGUM A, RAUTSCHY SA: NSAID and antioxidant prevention of Alzheimers disease: lessons from in vitro and animal models. Ann. NY Acad. Sci. (2004) 1035:68-84. (Pubitemid 40362327)
65. GELDOF AA: Nerve-growth-factordependent neurite outgrowth assay; a research model for chemotherapy-induced neuropathy. J. Cancer Res. Clin. Oncol. (1995) 121:657-660.
66. HOL EM, MANDYS V, SODAAR P, GISPEN WH, BAR PR: Protection by an ACTH4-9 analogue against the toxic effects of cisplatin and taxol on sensory neurons and glial cells in vitro. J. Neurosci. Res. (1994) 39:178-185.
67. SANO M: Radicicol and geldanamycin prevent neurotoxic effects of anti-cancer drugs on cultured embryonic sensory neurons. Neuropharmacol. (2001) 40:947-953. (Pubitemid 32510808)
68. APFEL SC: Neurotrophic factors in peripheral neuropathies: therapeutical implications. Brain Pathol. (1999) 9:393-413. (Pubitemid 29157723)
69. VERSTAPPEN CC, GELDOF AA, POSTMA TJ, HEIMANS JJ: In vitro protection from cisplatin-induced neurotoxicity by amifostine and its metabolite WR-1065. J. Neurooncol. (1999) 44(1):1-5. (Pubitemid 29515643)
70. VERSTAPPEN CC, POSTMA TJ, GELDOF AA, HEIMANS JJ: Amifostine protects against chemotherapy-induced neurotoxicity: an in vitro investigation. Anti-Cancer Res. (2004) 24(4):2337-2341. (Pubitemid 39166315)
71. CAVALETTI G, TREDICI G, MARMIROLI P, PETRUCCIOLI MG, BARAJON I, FABBRICA D: Morphometric study of the sensory neurons and peripheral nerve changes induced by chronic cisplatin (DDP) administration. Acta Neuropathol. (1992) 84:364-371.
72. PISANO C, PRATESI G, LACCABUE D et al.: Paclitaxel and cisplatin-induced neurotoxicity: a protective role of acetyl-Lcarnitine. Clin. Cancer. Res. (2003) 9:5756-5767. (Pubitemid 37499500)
73. DE SANTIS S, PACE A, BOVE L et al.: Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor. Clin. Cancer Res. (2000) 6:90-95. (Pubitemid 30064980)
74. CAVALETTI G, PEZZONI G, PISANO C, OGGIONI N, SALA F, ZOIA C: Cisplatin-induced peripheral neurotoxicity in rats reduces the circulating levels of nerve growth factor. Neurosci. Lett. (2002) 322:103-106. (Pubitemid 34212031)
75. TAGLIALATELA G, ANGELUCCI L, RAMACCI MT, WERRBACH-PEREZ K, JACKSON GF, PEREX-POLO R: Stimulation of nerve growth factor receptor in PC-12 cells by acetyl-L-carnitine. Biochem. Pharmacol. (1992) 44:577-585.
76. FISCHER SJ, PODRATZ JL, WINDEBANK AJ: Nerve growth factor rescue of cisplatin neurotoxicity is mediated through the high affinity receptor: studies in PC-12 cells and p75 null mouse dorsal root ganglia. Neurosci. Lett. (2001) 308:1-4. (Pubitemid 32607666)
77. MALGRANGE B, DELREE P, RIGO JM, BARON H, MOONEN G: Image analysis of neurite regeneration by adult rat dorsal root ganglion neurons in culture: quantification of the neurotoxicity of anticancer agents and its prevention by nerve growth factor or fibroblast growth factor, but not brain derived neurotrophic factor or neurotrophin-3. J. Neurosci. Meth. (1994) 53:111-122.
78. RADWAN IA, SAITO S, GOTO F: The neurotoxicity of local anesthetics on growing neurons: a comparative study of lidocaine, bupivacaine, mepivacaine and ropivacaine. Anesth. Analg. (2002) 94:319-324. (Pubitemid 34106821)
79. LIRK P, LONGATO S, RIEDER J, KLIMASCHEWSKI L: Cisatracurium, but not mivacurium, inhibits survival and axonal growth of neonatal and adult rat peripheral neurons in vitro. Neurosci. Lett. (2004) 365:153-155. (Pubitemid 38881644)
80. BRAT DJ, BRIMIJOIN S: Acrylamide and glycidamide impair neurite outgrowth in differentiating N1E 115 neuroblastoma without disturbing rapid bidirectional transport of organelles observed by video microscopy. J. Neurochem. (1993) 60:2145-2152. (Pubitemid 23148786)
81. GARLE MJ, FRY JR: Sensory nerves, neurogenic inflammation and pain: missing components of alternative irritation strategies: a review and a potential strategy. Altern. Lab. Anim. (2003) 31(3):295-316. (Pubitemid 36950603)
82. KLEMM M, SCHRATTENHOLZ A: Neurotoxicity of active compounds - establishment of hESC-lines and proteomics technologies for human embryo-and neurotoxicity screening and biomarker identification. ALTEX (2004) 21(Suppl. 3):41-48. (Pubitemid 38979456)
83. CONTI L, POLLARD SM, GORBA T et al.: Niche-independent symmetrical selfrenewal of a mammalian tissue stem cell. PLoS Biol. (2005) 3(9):e283.
84. WOBUS AM, BOHELER KR: Embryonic stem cells: Prospects for developmental biology and cell therapy. Physiol. Rev. (2005) 85:635-678. (Pubitemid 40404638)
85. BUZANSKA L, HABICH A, JURGA M, SYPECKA J, DOMANSKA-JANIK K: Human cord blood-derived neural stem cell line - possible implementation in studying neurotoxicity. Toxicol. In Vitro (2005) 19(7):991-999. (Pubitemid 41563238)
86. MORSHEAD CM, BENVENISTE P, ISCOVE NN, VAN DER KOOY D: Hematopoietic competence is a rare property of neural stem cells that may depend on genetic and epigenetic alterations. Nat. Med. (2002) 8:268-273. (Pubitemid 34250105)
87. ROSSI F, CATTANEO E: Opinion: neural stem cell therapy for neurological disease: dreams and reality. Nat. Rev. Neurosci. 3:401-409.
88. BLAAUBOER BJ: The necessity of biokinetic information in the interpretation of in vitro toxicity data. Altern. Lab. Anim. (2002) 30(Suppl. 2):85-91. (Pubitemid 36168718)